✓ Translated by DotMD AI Clinical Council Source: International journal of surgery (London, England) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38716987 ↗

Phase III Randomized Trial: Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07 (N = 442)

Original Paper Title: “Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07: a randomized controlled trial”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 442
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The KLASS-07 trial confirmed that TLDG is not different from LADG in terms of postoperative complications but has the advantages to reduce ileus and pulmonary complications. TLDG can be a good option to offer better QoL in terms of pain, body image, emotion, and anxiety at 3-6 months.
  • Study Design & Sample: Phase III Randomized Trial published in International journal of surgery (London, England) (N = 442 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in International journal of surgery (London, England) (2024), this phase iii randomized trial evaluating 442 human participants investigated: Strong evidence is lacking as no confirmatory randomized controlled trials (RCTs) have compared the efficacy of totally laparoscopic distal gastrectomy (TLDG) with laparoscopy-assisted distal gastrectomy (LADG). Key clinical takeaway: The KLASS-07 trial confirmed that TLDG is not different from LADG in terms of postoperative complications but has the advantages to reduce ileus and pulmonary complications. TLDG can be a good option to offer better QoL in terms of pain, body image, emotion, and anxiety at 3-6 months.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (International journal of surgery (London, England), 2024-08-01; N = 442; Rigor 87/100): The KLASS-07 trial confirmed that TLDG is not different from LADG in terms of postoperative complications but has the advantages to reduce ileus and pulmonary complications. TLDG can be a good option to offer better QoL in terms of pain, body image, emotion, and anxiety at 3-6 months.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: stomach-relief-ultra-strength-bismuth-subsalicylate → Rx: stomach-relief-24-7-life-by-7-eleven-bismuth-subsalicylate-tablet → Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: gastric-retention → Condition: retroperitoneal-abscess →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38716987: Phase III Randomized Trial: Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07 (N = 442)

3 of 3 Free Questions Remaining